(Q40684243)

English

Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate

scientific article published on 3 May 2016

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1 reference

based on heuristic

inferred from title

author name string

Chun Fang Shen

1

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Danielle Jacob

2

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Tao Zhu

3

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Alice Bernier

4

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Zhongqi Shao

5

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Xuefeng Yu

6

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Mehul Patel

7

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Stephane Lanthier

8

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Amine Kamen

9

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

language of work or name

0 references

publication date

3 May 2016

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

3381-3387

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Biology of adenovirus and its use as a vector for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Adenoviral vectors for gene therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Use of adenoviral vectors as veterinary vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Two different serum-free media and osmolality effect upon human 293 cell growth and adenovirus production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Innate immune response to adenovirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Strategies to overcome host immunity to adenovirus vectors in vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Large-scale adenovirus and poxvirus-vectored vaccine manufacturing to enable clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Intranasal mucosal boosting with an adenovirus-vectored vaccine markedly enhances the protection of BCG-primed guinea pigs against pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

High-throughput methods for combinatorial drug discovery

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Antibody-mediated immunity against tuberculosis: implications for vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Development and optimization of an adenovirus production process

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

From the first to the third generation adenoviral vector: what parameters are governing the production yield?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Single mucosal, but not parenteral, immunization with recombinant adenoviral-based vaccine provides potent protection from pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Empty capsids in column-purified recombinant adenovirus preparations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Good manufacturing practice production of adenoviral vectors for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.04.090

7 January 2021

Identifiers

10.1016/J.VACCINE.2016.04.090

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40684243&oldid=1904806471"